Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , appears to represent a notable development for obesity loss . Initial human trials have shown substantial losses in body mass , potentially surpassing existing weight-loss treatments. However , more study is required to fully determine its lasting impact and to… Read More